3 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Not approvedWill not start
To study the effect of high dose oral cholecalciferol suppletion on serum 25-OHD in elderly with osteoarthritis of the hip.
Approved WMOWill not start
A pilot study the effect of high dose oral cholecalciferol suppletion on serum 25-OHD in elderly with osteoarthritis of the hip.